Wellcome Leap logo
Program

CARE

Supports research reducing women's Alzheimer's risk through endocrinology-based biomarker and imaging discovery.

Wellcome LeapCooperative agreement

CARE (Cutting Alzheimer's Risk through Endocrinology) is part of Wellcome Leap's $50M new women's health initiative. The program targets a 50% reduction in women's lifetime risk of Alzheimer's disease — potentially preventing 54.5 million cases globally by 2050 — through three thrust areas: biomarker development, neuroimaging, and predictive modeling focused on hormonal and endocrine mechanisms.

BiotechMedtechNeurotech

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.

Last verified: 1 Jun 2026Source: wellcomeleap.org